|

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

RECRUITINGSponsored by Hunan Province Tumor Hospital
Actively Recruiting
SponsorHunan Province Tumor Hospital
Started2020-03-24
Est. completion2024-12-24
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04324151

Summary

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
* Potentially Resectable NSCLC
* Treatment Plan is Crizotinb or Standard Chemotherapy

Exclusion Criteria:

* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.